VYNE Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 169 K

LB filings
2025.11.06 21:03
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 169 K, beating the estimate of USD 100 K.

EPS: As of FY2025 Q3, the actual value is USD -0.17, missing the estimate of USD -0.13.

EBIT: As of FY2025 Q3, the actual value is USD -7.792 M.

Financial Metrics by Segment

Revenue

  • Royalty Revenues: $169,000 for the three months ended September 30, 2025, compared to $121,000 for the same period in 2024. For the nine months ended September 30, 2025, royalty revenues were $440,000, compared to $417,000 for the same period in 2024.

Operating Expenses

  • Research and Development: $5.3 million for the three months ended September 30, 2025, compared to $10.2 million for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses were $16.3 million, compared to $21.3 million for the same period in 2024.
    • Repibresib (VYN201): $2.1 million for the three months ended September 30, 2025, compared to $5.96 million for the same period in 2024. For the nine months ended September 30, 2025, expenses were $7.14 million, compared to $12.4 million for the same period in 2024.
    • VYN202: $2.41 million for the three months ended September 30, 2025, compared to $3.38 million for the same period in 2024. For the nine months ended September 30, 2025, expenses were $6.6 million, compared to $6.27 million for the same period in 2024.
    • Other Segment Items: $742,000 for the three months ended September 30, 2025, compared to $909,000 for the same period in 2024. For the nine months ended September 30, 2025, expenses were $2.52 million, compared to $2.59 million for the same period in 2024.
  • General and Administrative: $2.7 million for the three months ended September 30, 2025, compared to $3.0 million for the same period in 2024. For the nine months ended September 30, 2025, general and administrative expenses were $8.7 million, compared to $10.0 million for the same period in 2024.

Operating Loss

  • Operating Loss: $7.79 million for the three months ended September 30, 2025, compared to $13.1 million for the same period in 2024. For the nine months ended September 30, 2025, operating loss was $24.5 million, compared to $30.9 million for the same period in 2024.

Other Income, Net

  • Other Income, Net: $366,000 for the three months ended September 30, 2025, compared to $934,000 for the same period in 2024. For the nine months ended September 30, 2025, other income was $2.75 million, compared to $3.07 million for the same period in 2024.

Net Loss

  • Net Loss: $7.28 million for the three months ended September 30, 2025, compared to $12.2 million for the same period in 2024. For the nine months ended September 30, 2025, net loss was $21.6 million, compared to $27.8 million for the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: $29.4 million for the nine months ended September 30, 2025, compared to $25.0 million for the same period in 2024.
  • Net Cash Provided by Investing Activities: $28.9 million for the nine months ended September 30, 2025, compared to $10.6 million for the same period in 2024.
  • Net Cash Used in Financing Activities: $128,000 for the nine months ended September 30, 2025, compared to $9,000 for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: VYNE Therapeutics Inc. is focused on developing therapies for chronic inflammatory and immune-mediated conditions. The company is advancing its lead program, VYN202, an oral small molecule BD2-selective BET inhibitor, and has completed a Phase 1a trial with positive data. The company is also working on repibresib gel (VYN201), a topically administered small molecule pan-BET inhibitor, although the Phase 2b trial did not meet its primary endpoint.
  • Non-Core Business: The company is seeking an external partner for the continued development of repibresib gel and is conducting a strategic review to evaluate options to maximize stockholder value, including strategic partnerships, licensing opportunities, mergers, acquisitions, asset sales, or other potential paths.
  • Priority: The company has implemented cost reductions to extend its cash runway into the first half of 2027 and is evaluating opportunities for VYN202 and VYN201 as part of broader strategic alternatives.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.